Recursion Pharmaceuticals, Inc. RXRX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $753.92M+25.0% | $603.02M+50.2% | $401.43M-28.2% | $559.11M+89.3% | ||
| $812.85M+13.8% | $714.27M+63.0% | $438.14M-23.1% | $569.81M+6.6% | ||
| $103.93M-26.3% | $141.06M+63.1% | $86.51M-1.9% | $88.19M+36.3% | ||
| $162.16M+8.9% | $148.87M+186% | $52.06M+6,399% | $801K0.0% | ||
| $309.9M-7.7% | $335.86M+822% | $36.44M+2,690% | $1.31M-5.7% | ||
| $1.47B+1.8% | $1.45B+122% | $653.7M-6.8% | $701.29M+14.9% | ||
| $76.45M+133% | $32.75M+125% | $14.55M-8.0% | $15.81M+2.3% | ||
| $37.61M-39.1% | $61.77M+69.6% | $36.43M-35.8% | $56.73M+467% | ||
| $9.09M+7.9% | $8.43M+20,449% | $41K— | —— | ||
| $147.71M-21.2% | $187.47M+101% | $93.17M-7.1% | $100.27M+115% | ||
| $9.56M-49.7% | $19.02M+1,628% | $1.1M+105% | $536K-15.3% | ||
| $343.27M-17.0% | $413.82M+117% | $190.26M-11.7% | $215.48M+220% | ||
| 2B+49,999,900% | 4K+100% | 2K0.0% | 2K0.0% | ||
| -$2.08B-45.0% | -$1.43B-47.9% | -$967.62M-51.3% | -$639.56M-59.9% | ||
| $1.13B+9.3% | $1.03B+123% | $463.44M-4.6% | $485.81M-10.5% | ||
| $1.47B+1.8% | $1.45B+122% | $653.7M-6.8% | $701.29M+14.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Recursion Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 5.47 — current assets exceed current liabilities.
- Where does Recursion Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.